Asthma Clinical Trial
Official title:
The Effects of Methacholine Challenge Administered Using Three Different Nebulizers on Small Airways Function
The objective of this study is to examine the functional effects of methacholine challenge on small airways using three different nebulizers to generate particles with HMAD suitable for distribution in small, intermediate and large airways.Pulmonary function will be assessed using plethysmography and impulse oscillation techniques. Eight asthmatic subjects (>18 years, both sexes) who are stable clinically and require only intermittent ß2-agonist treatment will be recruited to undergo methacholine challenges for an in vivo, dose-finding observational study. Three separate methacholine challenges will be carried out using each of the three different nebulizers. After each challenge, pulmonary function tests will be performed on subjects to assess functional changes in large and small airways. Results of the tests will be compared between the three nebulizers. These experiments will demonstrate whether or not functional changes occur in small airways in response to methacholine, as measured by pulmonary function tests after selectively targeting small airways using the nebulizer which generates small particles. The results from these experiments will give us a better understanding of the role of small airways in methacholine-induced bronchoconstriction in asthmatics, and will compare sensitivity of plethysmography compared to forced oscillation for detecting changes in small airways.
This study will measure changes in small airways by plethysmography and impulse oscillation
following delivery of methacholine using nebulizers designed to deliver to the small
(Wright), intermediate (PARI LC® Plus) and large (PARI SinuStar™ ) airways.
Assessment of small airways involvement by plethysmography will include Residual Volume
(RV), Forced Vital Capacity (FVC) and Peak Inspiratory and Expiratory Flow rates (PIF and
PEF, respectively). Impulse oscillation will include measures of large and small airways
resistance.
Baseline Spirometry
Baseline FEV1 and VC will be registered using a water spirometer.
Methacholine Challenge (Screening)
Methacholine inhalation will be performed as described by Cockcroft (1996). Subjects are
instructed to wear noseclips and to breathe normally from the mouthpiece during the 2-minute
inhalation period. Subjects inhale normal saline, then doubling concentrations of
methacholine from a Wright nebulizer for 2 minutes each. FEV1 is measured at 30, 90, 180 and
300 seconds after each inhalation. Spirometry is measured with a Collins water sealed
spirometer and kymograph. The test is terminated when a fall in FEV1 of 20% of the baseline
value occurs, and the methacholine PC20 is calculated.
Methacholine Challenge
During the second visit, subjects will be randomized to inhale from a nebulizer that
generates particles with HMAD suitable for distribution either in small, intermediate or
large airways. Subjects will inhale doubling concentrations of methacholine for 2 minutes
each. Immediately after each inhalation, pulmonary function tests will be performed on the
subjects via plethysmography. Measurements will be made at intervals of 30 seconds, 60
seconds, 3 minutes and 5 minutes (or until a fall in FEV1 of 20% or more of baseline is
reached). The methacholine test is terminated when a fall in FEV1 of 20% or more of the
baseline value is reached. After a recovery time of 1 hour, the same doses will be
re-administered and pulmonary function tests will again be performed, this time via impulse
oscillation. The same procedure will be repeated for the third and fourth visits with the
remaining nebulizers (selected randomly). The nebulizers that will be used to target certain
airways are the Wright nebulizer (small), the PARI LC® Plus nebulizer (medium) and the PARI
SinuStar™ nebulizer (large).
Plethysmography
Pulmonary function tests will be performed on subjects after methacholine challenges via
plethysmography. Various tests will be performed that will allow for different lung function
measures. To characterize which measurements are indicative of large or small airways
function, measurements from the three nebulizer groups will be compared. Potential measures
of small airway function include Functional Residual Capacity (FRC), Residual Volume (RV),
Forced Vital Capacity (FVC) and Peak Inspiratory and Expiratory Flow Rates (PIF and PEF,
respectively) (Knudson et al., 1980). Nitrogen washout will also be performed with the body
box to measure airway distensibility, or the relationship between airway caliber and lung
volume (Brown et al., 2004).
Impulse Oscillation
Pulmonary function tests will be performed on subjects after methacholine challenges via
impulse oscillation. This device uses a loudspeaker to generate pressure and flow and by
generating these at various frequencies, specifically differentiates between large and small
airways obstruction (Otis et al., 1956). Results will be compared between the three
nebulizer groups after specifically targeting certain airways.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|